SUBSCRIBE
SUBSCRIBE

Nick Paul Taylor

Nick is a freelance writer who has been reporting on the global life sciences industry since 2008. With a BSc in biology, Nick writes about the science and business of biopharma and medtech for numerous healthcare publications. He can be reached at nick.paul.taylor@gmail.com or on LinkedIn.

3d rendering of a plastic jar with medical pills on a hand truck on blue background. Medicine and health. Bottles and containers. Healthcare industry.
Manufacturing
Trump’s Push To Shore Up Pharma Supply Chain With US API Welcomed but Questioned
While trade groups hail the executive order as a national health security opportunity, analysts warn that production costs could go up in the near term.
September 2, 2025
 · 
4 min read
 · 
Nick Paul Taylor
a robotic assembly line with vials
Manufacturing
Drugmakers Hail Early Wins in AI-Driven Transformation of Manufacturing
Companies have claimed improvements to yield, batch consistency and output while acknowledging the risks and challenges created by the technology.
August 26, 2025
 · 
5 min read
 · 
Nick Paul Taylor
Hands in black and white dropping a collection of pills on a pink background
Manufacturing
Oral Wegovy’s Pending Approval Puts Spotlight on Viability of High-Dose Peptides
While the 10-fold increase in dose over injectable Wegovy has raised questions about the launch, Novo Nordisk has assured investors it has the manufacturing capacity to roll out oral semaglutide without restrictions on supply.
August 19, 2025
 · 
5 min read
 · 
Nick Paul Taylor
concept of a perilous situation with a man who finds himself suspended above the void while standing at the edge of the cliffs.
GLP-1
A Compounding Problem: How GLP-1s Drove Novo Nordisk’s Rapid Rise and Fall
Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma recover?
August 13, 2025
 · 
5 min read
 · 
Nick Paul Taylor
Isometric projection of a medieval castle on an island
Manufacturing
Obesity Leaders Dig Manufacturing Moats To Defend Injectable GLP-1 Empires
Leaders at Eli Lilly believe heavy investment in the company’s manufacturing footprint “sets a high standard that newcomers may find challenging to match.” At least one of those newcomers disagrees.
August 12, 2025
 · 
6 min read
 · 
Nick Paul Taylor
Biontech SE headquarters with company flags, German biotechnology company, BioNTech Manufacturing, development and production active immunotherapeutic agents in Mainz, Germany - September 7, 2024
Earnings
BioNTech Commits to Infectious Diseases Amid Questions Over Vaccine Demand
The company expects that the U.S. COVID-19 vaccination rate will be “maybe a couple of points lower” than the prior level of around 20% but that pricing and Comirnaty’s market share will hold steady.
August 4, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Protection From Tariffs as an An umbrella that shields against import and export tariff taxes as a trade war storm increasing prices and straining supply chains as a business metaphor and a symbol for resilience in times of crisis and economic downturn.
Earnings
Sanofi Confident Tariffs Will Have Limited Impact on Finances in 2025
For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU.
July 31, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Biogen’s headquarters in Massachusetts
Manufacturing
Biogen Commits $2B To Expand US Drug Production Amid Tariff Talk
The biotech is planning to expand antisense oligonucleotide capabilities and infrastructure on campuses that already produce drugs such as the ALS therapy Qalsody.
July 21, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Online Medicine or internet pharmacy services as a pharmacist or web doctor and medical health service or digital healthcare for purchase and delivery of medications as Telemedicine and Teleconsultations.
Drug Pricing
BMS, Pfizer Join DTC Trend, Offering Eliquis to Patients for 40% Below List Price
In advance of CMS’ negotiated price for the blood thinner taking effect next year, partners Bristol Myers Squibb and Pfizer pitched the direct-to-consumer program as a way to allow uninsured, underinsured and self-pay patients to pay less out of pocket.
July 17, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Johnson & Johnson's business center in Switzerland
Earnings
J&J Targets $50B Oncology Sales By 2030: Updated
Johnson & Johnson’s $23.7 billion in second-quarter earnings, driven by cancer and neuroscience drugs, exceeded analyst expectations, while CEO Joaquin Duato set a target of $50 billion in oncology sales by 2030.
July 16, 2025
 · 
2 min read
 · 
Nick Paul Taylor
People standing on cracked ground. Concept vector illustration, sketch
Weight loss
Novo Nordisk’s Termination of Hims & Hers Deal Reignites Compounding Row
Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the “litigation risk is back on the table” now that the Danish pharma has stepped away.
July 9, 2025
 · 
4 min read
 · 
Nick Paul Taylor
Man reaching the top and having success, throwing cash in air. Being successful in finance concept. Vector illustration
Infectious disease
Gilead Eyes HIV Market Domination With Twice-Yearly Yeztugo as GSK Trails
Analysts believe that Gilead’s new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say about it.
July 2, 2025
 · 
4 min read
 · 
Nick Paul Taylor
Business
TIGIT Turmoil: How Pharma Burned Billions on Failed Immuno-Oncology Projects
Leading companies spent $1.4 billion upfront on licensing deals and embarked on vast R&D programs. Clinical setbacks mean many companies are unlikely to ever recoup their investments.
June 25, 2025
 · 
5 min read
 · 
Nick Paul Taylor
Judge hiiting tiny man by gavel. Bankruptcy, lawsuit, protest concept. Vector illustration.
Legal
BioNTech Attacked CureVac’s ‘Failed’ COVID Vaccine Program. The Rivals Are Now Merging
BioNTech said in 2022 that it faced “threats of a groundless patent infringement suit” from a company that was “unable to bring to market any product to help in the fight against COVID-19.” Now, the mRNA biotech is buying that very company.
June 18, 2025
 · 
4 min read
 · 
Nick Paul Taylor
Pictured: Eli Lilly's biotechnology center in California
Obesity
Lilly Inks Deal Worth up to $870M To Develop Long-Acting GLP-1 Obesity Drugs
Eli Lilly joins up with Camurus to make long-acting versions of the pharma’s obesity and diabetes drugs, joining the industry’s growing pipeline of programs that are differentiated by the frequency of dosing.
June 4, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Load More